7517-99-9

Usage

Uses

Used in Polymer Synthesis:
5-(Hydroxymethyl)-1,3-oxazolidin-2-one is used as a monomer for the synthesis of polymeric materials, leveraging its ability to form stable and functional polymers with diverse applications.
Used in Pharmaceutical Production:
In the Pharmaceutical Industry, 5-(Hydroxymethyl)-1,3-oxazolidin-2-one is utilized as a key intermediate in the manufacturing process of various drugs, contributing to the development of new medicinal compounds.
Used in Agrochemical Formulation:
5-(Hydroxymethyl)-1,3-oxazolidin-2-one is employed as an intermediate in the production of agrochemicals, playing a crucial role in the synthesis of effective and environmentally friendly pesticides and fertilizers.
Used in Biodegradable Polymer Development:
5-(Hydroxymethyl)-1,3-oxazolidin-2-one is used as a building block in the creation of biodegradable polymers, which is significant for reducing environmental impact and promoting sustainability in various industries.
Used in Drug Delivery Systems:
5-(Hydroxymethyl)-1,3-oxazolidin-2-one is applied in the design of drug delivery systems to enhance the bioavailability and targeting of pharmaceutical agents, improving the efficacy and safety of drug administration.

Upstream product

• 113420-80-7 Acetic acid (S)-2-oxo-oxazolidin-5-ylmethyl ester 
• 112663-80-6 (S)-2-oxazolidinone-5-carboxylic acid benzyl ester 
• 61278-21-5 (S)-3-Amino-1,2-propanediol 
• 105-58-8 Diethyl carbonate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 330555-60-7 (S)-5-triphenylmethoxymethyl-1,3-oxazolidin-2-one 
• 56-81-5 glycerol 
• 57-13-6 urea 
• 852805-35-7 (S)-5-(4-methoxyphenoxymethyl)-1,3-oxazolidin-2-one 

Downstream Products

• 109794-68-5 (S)-(2-oxo-1,3-oxazolidin-5-yl)methyl 4-methylbenzenesulfonate 
• 29218-21-1 5-(hydroxymethyl)-3-phenyl-2-oxooxazolidine 
• 29218-27-7 toloxatone 
• 57558-39-1 5-m-tolyloxymethyl-oxazolidin-2-one 
• 1369530-77-7 3-(4-bromo-3-fluorophenyl)-5-(hydroxymethyl)oxazolidin-2-one 
• 7517-99-9 (S)-5-(hydroxymethyl)-1,3-oxazolidin-2-one 
• 97859-49-9 (R)-5-(hydroxymethyl)-1,3-oxazolidin-2-one 
• 513068-96-7 3-(3-fluoro-4-morpholin-4-yl-phenyl)-5-hydroxymethyl-oxazolidin-2-one 
• 1222521-08-5 5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)oxazolidin-2-one 
• 97899-38-2 (2-oxo-1,3-oxazolidin-5-yl)-methyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

QUINAZOLINE COMPOUND FOR EGFR INHIBITION

Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells

Cancer cells reprogram their metabolism to support growth and to mitigate cellular stressors. The serine synthesis pathway has been identified as a metabolic pathway frequently altered in cancers and there has been considerable interest in developing pharmacological agents to target this pathway. Here, we report a series of indole amides that inhibit human 3-phosphoglycerate dehydrogenase (PHGDH), the enzyme that catalyzes the first committed step of the serine synthesis pathway. Using X-ray crystallography, we show that the indole amides bind the NAD+ pocket of PHGDH. Through structure-based optimization we were able to develop compounds with low nanomolar affinities for PHGDH in an enzymatic IC50 assay. In cellular assays, the most potent compounds inhibited de novo serine synthesis with low micromolar to sub-micromolar activities and these compounds successfully abrogated the proliferation of cancer cells in serine free media. The indole amide series reported here represent an important improvement over previously published PHGDH inhibitors as they are markedly more potent and their mechanism of action is better defined.

Heterometallic metal-organic framework-templated synthesis of porous Co3O4/ZnO nanocage catalysts for the carbonylation of glycerol

The efficient synthesis of glycerol carbonate (GLC) has recently received great attention due to its significance in reducing excess glycerol in biodiesel production as well as its promising applications in several industrial fields. However, the achievement of high conversion and high selectivity of GLC from glycerol in heterogeneous catalytic processes remains a challenge due to the absence of high-performance solid catalysts. Herein, highly porous nanocage catalysts composed of well-mixed Co3O4 and ZnO nanocrystals were successfully fabricated via a facile heterometallic metal-organic framework (MOF)-templated synthetic route. Benefiting from a high porosity and the synergistic effect between Co3O4 and ZnO, the as-prepared composite catalysts exhibited a significantly enhanced production efficiency of GLC in the carbonylation reaction of glycerol with urea compared to the single-component counterparts. The yield of GLC over the Co50Zn50-350 catalyst reached 85.2%, with 93.3% conversion and near 91% GLC selectivity, and this catalytic performance was superior to that over most heterogeneous catalysts. More importantly, the proposed templated synthetic strategy of heterometallic MOFs facilitates the regulation of catalyst composition and surface structure and can therefore be potentially extended in the tailoring of other metal oxide composite catalysts.

Chemicals from biomass: Synthesis of glycerol carbonate by transesterification and carbonylation with urea with hydrotalcite catalysts. The role of acid-base pairs

Synthesis of glycerol carbonate has been performed by transesterification of ethylene carbonate with glycerol catalyzed by basic oxides (MgO, and CaO), and mixed oxides (Al/Mg, Al/Li) derived from hydrotalcites. The results showed that the optimum catalyst in terms of activity and selectivity is a strong basic Al/Ca-mixed oxide (AlCaMO) which is able to catalyze the reaction at low temperature (35 °C), and low catalyst loading (0.5 wt%) giving high glycerol conversions with 98% selectivity to glycerol carbonate. When the synthesis of glycerol carbonate was carried out by carbonylation of glycerol with urea, the results showed that balanced bifunctional acid-base catalysts where the Lewis acid activates the carbonyl of the urea and the conjugated basic site activates the hydroxyl group of the glycerol were the most active and selective catalysts.

Lipase-mediated resolution of 3-hydroxy-4-trityloxybutanenitrile: synthesis of 2-amino alcohols, oxazolidinones and GABOB

Lipase-mediated kinetic resolution of 3-hydroxy-4-trityloxybutanenitrile gave the (S)-alcohol and (R)-acetate in good yields and high enantioselectivities. The resolution using Pseudomonas cepacia lipase (Burkholderia cepacia) immobilized on modified cera

New chemoenzymatic pathway for β-adrenergic blocking agents

The lipase mediated kinetic resolution of pharmaceutically important β-hydroxy nitriles is described in high enantiomeric excesses and good yields. Some of the chiral β-hydroxy nitriles have been employed in the synthesis of β-adrenergic blocking agents such as propranolol, alprenolol and moprolol. This protocol has also been extended for the enantiopure preparation of 5-(4-tosyloxymethyl)-1,3-oxazolidine-2-one and 3-hydroxy-4-tosyloxybutanenitrile, chiral intermediates of high synthetic value.

Synthesis and antibacterial evaluation of oxazolidin-2-ones structurally related to linezolid

Compounds structurally related to the known antimicrobial drug linezolid were selected in order to evaluate the influence of electron-withdrawing properties and altered geometric features as a result of the N-substituent modification. After a preliminary

Resolution of 5-hydroxymethyl-2-oxazolidinone by preferential crystallization and investigations on the nature of the racemates of some 2-oxazolidinone derivatives

After ascertaining its conglomerate nature by DSC and solid-state IR analyses, 5-hydroxymethyl-2-oxazolidinone 1, whose enantiomers are very important synthons, was efficiently resolved without chiral auxiliaries by preferential crystallization from a supersaturated isopropanolic solution of the racemate, slightly enriched in one enantiomer (3.7% ee). Favourable conditions to the entrainment were defined utilizing the previously constructed ternary phase diagram {(R)-1, (S)-1, 2-propanol}. Furthermore, the investigations were extended to other chiral 2-oxazolidinones with a functionalized methyl at the 5- or 4-position finding that 5-tosyloxymethyl-2-oxazolidinone is a racemic compound, whereas just the corresponding mesylate is a conglomerate as the parent alcohol 1. Interestingly, 4-hydroxymethyl-2-oxazolidinone 4 proved to be a racemic compound in contrast with its positional isomer 1 demonstrating how a relatively fine variation in the molecular structure can unpredictably influence the crystalline nature of the racemate. The X-ray structure determination carried out on (S)-(+)-1, (±)-4 and (R)-(+)-4 enlightened the importance of the hydrogen bond in determining different supramolecular assembling in the two homochiral compounds with respect to the racemic one and allowed a correlation with the stability of the crystal to be made.

OXAZOLIDINONE DERIVATIVES N-SUBSTITUTED BY A BICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS

Compounds of formula (I) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of formula (I). Compoun

Efficient Pathways to (R)- and (S)-5-Hydroxymethyl-2-oxazolidinone and some Derivatives

2-Oxazolidinones are a very interesting class of compounds due to their various pharmacological effects.Two new syntheses of enantiomerically pure (R)- and (S)-5-hydroxymethyl-2-oxazolidinone have been developed starting with D-mannitol, L-ascorbic acid and (R)- or (S)-malic acid. (R)- and (S)-5-hydroxymethyl-2-oxazolidinone have been used to synthesize some new homochiral 2-oxazolidinone derivatives.